On October 10, 2024 Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, reported that four abstracts have been accepted for poster presentation at the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics, to take place in Barcelona, Spain, October 23 – 25, 2024 (Press release, Aprea, OCT 10, 2024, View Source [SID1234647133]). Details on the posters are below.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are very pleased to have these posters featured at the upcoming EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium, showcasing the ongoing progress in our oncology pipeline of DNA damage response (DDR) inhibitors," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. "This symposium provides a great opportunity to share updates on our two clinical stage candidates, APR-1051 and ATRN-119, with the international oncology community."
Poster Details
Clinical:
Title: Safety and Preliminary Efficacy of APR-1051, a WEE1 Inhibitor, in a Phase 1 Study of Patients with Cancer-Associated Gene Alterations (ACESOT-1051)
Session date/ time: Wednesday, October 23rd, 12:00 – 19:00 CET
Location: Exhibition Hall
Poster #: 77
Title: ATRN-119, a Novel Macrocyclic ATR Inhibitor, in Patients with Advanced Solid Malignancies: A Phase 1/2a Trial (ABOYA-119)
Session date/ time: Friday, October 25th, 09:00 – 15:00 CET
Location: Exhibition Hall
Poster#: 348
Preclinical
Title: The novel WEE1i, APR-1051, does not substantially off-target PLK1, PLK2, or PLK3 and exhibits favorable in vivo characteristics for treating CCNE1-overexpressing cancers
Session date/ time: Friday, October 25th, 09:00 – 15:00 CET
Location: Exhibition Hall
Poster #: 335
Title: Development and testing of a first-in-class series of macrocyclic ATR inhibitors for cancer treatment
Session date/ time: Friday, October 25th, 09:00 – 15:00 CET
Location: Exhibition Hall
Poster #: 336
Copies of the posters will be available on the "Investor Resources" page of the Aprea corporate website at the conclusion of the meeting